Immune-related adverse events are associated with favorable clinical outcomes in esophageal cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. [PDF]
Fan J, Chen D, Jia L.
europepmc +1 more source
Association between antibiotic exposure and survival outcomes in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. [PDF]
Chen S +8 more
europepmc +1 more source
Small-molecule inhibitors and checkpoint inhibitors in KRAS G12C NSCLC: balancing efficacy and toxicity. [PDF]
Wagener EDA, Noordhof AL, van Geffen WH.
europepmc +1 more source
Catechol-functionalized carbon nanofibers enabling ultrafine CoFe<sub>2</sub>O<sub>4</sub> nanorods for high-performance bifunctional oxygen electrocatalysis and Zn-air batteries. [PDF]
Awan RJ +4 more
europepmc +1 more source
Emerging antibody-drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting. [PDF]
Wang X +6 more
europepmc +1 more source
Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions. [PDF]
Ye H, Wei Y, He X, Wei X.
europepmc +1 more source
Early on-treatment alpha-fetoprotein and des-gamma-carboxy prothrombin responses are associated with outcomes in unresectable hepatocellular carcinoma receiving transarterial chemoembolization, tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors. [PDF]
Liu Y +5 more
europepmc +1 more source

